This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
None of the Markov transition probabilities, including the natural history and treatment response probabilities, were reported in the article. The authors stated that the model was presented in greater detail elsewhere (see Bennett et al., Other Publications of Related Interest) .
Study designs and other criteria for inclusion in the review
Observational studies were used to estimate the natural history of disease. The response rates for antiviral treatment were derived from the results of clinical trials of patients with chronic HCV, which used the same treatment regime (recombinant IFN-A2b at a fixed dose of 3 million U, 3 times weekly for 6 months). The studies included in the review also had systematic follow-up, liver biopsy slides available for analysis, and study databases available for review. There was no indication that the review was systematic.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
The authors used a single pathologist, who was blinded, to review the information and to establish the correlation between histologic findings and response.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Eighteen primary studies were included in the review.
Methods of combining primary studies
The authors reanalysed pooled data from 5 clinical trials involving 287 patients to estimate treatment response. Transition probabilities for the natural history of chronic HCV were selected from the literature. The authors stated that this involved pooling the data where the follow-up was short or the sample size was small.
Investigation of differences between primary studies
The authors reported that likelihood estimates were reviewed by an expert panel of hepatologists and statisticians, and were modified where appropriate. This overcame some of the differences between the primary studies. The authors did not discuss differences or provide potential explanations for their existence.
Results of the review
None of the probabilities used in the model were reported. See the 'Estimate of Measure of Benefit' section for related effectiveness results.
Methods used to derive estimates of effectiveness

Measure of benefits used in the economic analysis
The summary measure of benefits was the QALYs. Utility values, which placed a weight on HCV states, were obtained from a group of American hepatologists using standard gamble and time trade-off methodology. The authors reported that these weights were checked with UK hepatologists.
Direct costs
The costing was carried out from the perspective of UK commissioning authorities and was reported to have been based on "typical UK management of HCV disease in each potential health state". The costs were discounted at 6%, which was appropriate for the long time horizon of the model. The analysis focused on the costs of hepatic complications and treatment. The unit costs were reported separately and were derived from actual data (e.g. drug costs from the British National Formulary) and other published tariffs. The Hospital and Community Health Services Index was used to adjust the estimates to 1998/9 values. The quantities were determined in the model.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were not included in the analysis, but were not relevant given the main perspective of the study. However, the authors suggested that, where possible, a wider societal perspective was adopted. It was unclear which, if any, of the costs were estimated from such a perspective.
Currency
UK pounds sterling ().
Sensitivity analysis
One-way sensitivity analyses were conducted to assess the impact of varying the cost of combination therapy, the cost of treating the consequences of HCV infection, and the annual likelihood of progressive liver disease.
Estimated benefits used in the economic analysis
In the analysis of combination therapy versus no treatment, no treatment gave 22.8 QALYs and combination therapy gave 27.6 QALYs. Therefore, the marginal effectiveness of combination therapy was 4.82.
In the analysis of combination therapy versus monotherapy, monotherapy gave 24.7 QALYs and combination therapy gave 27.6 QALYs. Therefore, the marginal effectiveness of combination therapy was 2.95.
Cost results
In the analysis of combination therapy versus no treatment, no treatment cost 13,729 and combination therapy cost 14,456. Therefore, the marginal cost of combination therapy was 523.47.
In the analysis of combination therapy versus monotherapy, monotherapy cost 14,363 and combination therapy cost 14,456. Therefore, the marginal cost of combination therapy was 93.93.
Synthesis of costs and benefits
In the analysis of combination therapy versus no treatment, the marginal cost-effectiveness (cost per QALY) of combination therapy was 151. The discounted marginal cost-effectiveness was 3,791. It increased because, comparatively, the benefits were spread over several years and the costs were not.
